Improving the quality of cancer clinical trials: workshop summary
Gespeichert in:
| Format: | Elektronisch E-Book |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
Washington, D.C.
National Academies Press
c2008
|
| Schlagworte: | |
| Beschreibung: | Includes bibliographical references |
| Beschreibung: | xii, 124 p. |
| ISBN: | 9780309116688 0309116686 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV044108813 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 170217s2008 |||| o||u| ||||||eng d | ||
| 020 | |a 9780309116688 |9 978-0-309-11668-8 | ||
| 020 | |a 0309116686 |9 0-309-11668-6 | ||
| 035 | |a (ZDB-30-PAD)EBC3378368 | ||
| 035 | |a (ZDB-89-EBL)EBL3378368 | ||
| 035 | |a (OCoLC)560530759 | ||
| 035 | |a (DE-599)BVBBV044108813 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 082 | 0 | |a 362.196/994007 |2 22 | |
| 245 | 1 | 0 | |a Improving the quality of cancer clinical trials |b workshop summary |c National Cancer Policy Forum, Margie Patlack and Sharyl Nass, rapporteurs |
| 264 | 1 | |a Washington, D.C. |b National Academies Press |c c2008 | |
| 300 | |a xii, 124 p. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 500 | |a Includes bibliographical references | ||
| 505 | 0 | |a Introduction -- New clinical trial designs. Phase 0 trials -- Adaptive trial designs -- Targeting multiple pathways with multiple drugs -- Preclinical model systems -- Molecular imaging. Current and developing methods -- Challenges of molecular imaging -- Screening for predictive markers. The challenges of clinical validation -- Bioimaging predictive markers -- Clinical translation -- Panel discussion -- Costs of clinical trials. Regulatory costs -- Patient accrual -- Global outsourcing -- Time is money -- Public-private collaborations -- Regulatory issues. Regulatory barriers to innovation -- Patient advocacy perspective -- Regulation of in vitro diagnostics -- Regulatory issues in improving cancer clinical trials -- Reports from the case study discussion groups. Adaptive trial design -- Phase 0 trials -- Imaging -- Use of proteomics/genomics to assign therapy in lung cancer -- Use of genetics/genomics to assign therapy | |
| 650 | 4 | |a Cancer |x Treatment |z United States | |
| 650 | 4 | |a Clinical trials | |
| 651 | 4 | |a USA | |
| 700 | 1 | |a Patlak, Margie |e Sonstige |4 oth | |
| 700 | 1 | |a Nass, Sharyl J. |e Sonstige |4 oth | |
| 710 | 2 | |a National Cancer Policy Forum (U.S.) |e Sonstige |4 oth | |
| 710 | 2 | |a Institute of Medicine (U.S.) |e Sonstige |4 oth | |
| 912 | |a ZDB-30-PAD | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-029515658 | ||
Datensatz im Suchindex
| _version_ | 1804177182633754624 |
|---|---|
| any_adam_object | |
| building | Verbundindex |
| bvnumber | BV044108813 |
| collection | ZDB-30-PAD |
| contents | Introduction -- New clinical trial designs. Phase 0 trials -- Adaptive trial designs -- Targeting multiple pathways with multiple drugs -- Preclinical model systems -- Molecular imaging. Current and developing methods -- Challenges of molecular imaging -- Screening for predictive markers. The challenges of clinical validation -- Bioimaging predictive markers -- Clinical translation -- Panel discussion -- Costs of clinical trials. Regulatory costs -- Patient accrual -- Global outsourcing -- Time is money -- Public-private collaborations -- Regulatory issues. Regulatory barriers to innovation -- Patient advocacy perspective -- Regulation of in vitro diagnostics -- Regulatory issues in improving cancer clinical trials -- Reports from the case study discussion groups. Adaptive trial design -- Phase 0 trials -- Imaging -- Use of proteomics/genomics to assign therapy in lung cancer -- Use of genetics/genomics to assign therapy |
| ctrlnum | (ZDB-30-PAD)EBC3378368 (ZDB-89-EBL)EBL3378368 (OCoLC)560530759 (DE-599)BVBBV044108813 |
| dewey-full | 362.196/994007 |
| dewey-hundreds | 300 - Social sciences |
| dewey-ones | 362 - Social problems and services to groups |
| dewey-raw | 362.196/994007 |
| dewey-search | 362.196/994007 |
| dewey-sort | 3362.196 6994007 |
| dewey-tens | 360 - Social problems and services; associations |
| discipline | Soziologie |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02254nmm a2200397zc 4500</leader><controlfield tag="001">BV044108813</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">170217s2008 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780309116688</subfield><subfield code="9">978-0-309-11668-8</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0309116686</subfield><subfield code="9">0-309-11668-6</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-30-PAD)EBC3378368</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-89-EBL)EBL3378368</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)560530759</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV044108813</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">362.196/994007</subfield><subfield code="2">22</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Improving the quality of cancer clinical trials</subfield><subfield code="b">workshop summary</subfield><subfield code="c">National Cancer Policy Forum, Margie Patlack and Sharyl Nass, rapporteurs</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Washington, D.C.</subfield><subfield code="b">National Academies Press</subfield><subfield code="c">c2008</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">xii, 124 p.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">Introduction -- New clinical trial designs. Phase 0 trials -- Adaptive trial designs -- Targeting multiple pathways with multiple drugs -- Preclinical model systems -- Molecular imaging. Current and developing methods -- Challenges of molecular imaging -- Screening for predictive markers. The challenges of clinical validation -- Bioimaging predictive markers -- Clinical translation -- Panel discussion -- Costs of clinical trials. Regulatory costs -- Patient accrual -- Global outsourcing -- Time is money -- Public-private collaborations -- Regulatory issues. Regulatory barriers to innovation -- Patient advocacy perspective -- Regulation of in vitro diagnostics -- Regulatory issues in improving cancer clinical trials -- Reports from the case study discussion groups. Adaptive trial design -- Phase 0 trials -- Imaging -- Use of proteomics/genomics to assign therapy in lung cancer -- Use of genetics/genomics to assign therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cancer</subfield><subfield code="x">Treatment</subfield><subfield code="z">United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Clinical trials</subfield></datafield><datafield tag="651" ind1=" " ind2="4"><subfield code="a">USA</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Patlak, Margie</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nass, Sharyl J.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="710" ind1="2" ind2=" "><subfield code="a">National Cancer Policy Forum (U.S.)</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="710" ind1="2" ind2=" "><subfield code="a">Institute of Medicine (U.S.)</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-30-PAD</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-029515658</subfield></datafield></record></collection> |
| geographic | USA |
| geographic_facet | USA |
| id | DE-604.BV044108813 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T07:43:54Z |
| institution | BVB |
| isbn | 9780309116688 0309116686 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-029515658 |
| oclc_num | 560530759 |
| open_access_boolean | |
| physical | xii, 124 p. |
| psigel | ZDB-30-PAD |
| publishDate | 2008 |
| publishDateSearch | 2008 |
| publishDateSort | 2008 |
| publisher | National Academies Press |
| record_format | marc |
| spelling | Improving the quality of cancer clinical trials workshop summary National Cancer Policy Forum, Margie Patlack and Sharyl Nass, rapporteurs Washington, D.C. National Academies Press c2008 xii, 124 p. txt rdacontent c rdamedia cr rdacarrier Includes bibliographical references Introduction -- New clinical trial designs. Phase 0 trials -- Adaptive trial designs -- Targeting multiple pathways with multiple drugs -- Preclinical model systems -- Molecular imaging. Current and developing methods -- Challenges of molecular imaging -- Screening for predictive markers. The challenges of clinical validation -- Bioimaging predictive markers -- Clinical translation -- Panel discussion -- Costs of clinical trials. Regulatory costs -- Patient accrual -- Global outsourcing -- Time is money -- Public-private collaborations -- Regulatory issues. Regulatory barriers to innovation -- Patient advocacy perspective -- Regulation of in vitro diagnostics -- Regulatory issues in improving cancer clinical trials -- Reports from the case study discussion groups. Adaptive trial design -- Phase 0 trials -- Imaging -- Use of proteomics/genomics to assign therapy in lung cancer -- Use of genetics/genomics to assign therapy Cancer Treatment United States Clinical trials USA Patlak, Margie Sonstige oth Nass, Sharyl J. Sonstige oth National Cancer Policy Forum (U.S.) Sonstige oth Institute of Medicine (U.S.) Sonstige oth |
| spellingShingle | Improving the quality of cancer clinical trials workshop summary Introduction -- New clinical trial designs. Phase 0 trials -- Adaptive trial designs -- Targeting multiple pathways with multiple drugs -- Preclinical model systems -- Molecular imaging. Current and developing methods -- Challenges of molecular imaging -- Screening for predictive markers. The challenges of clinical validation -- Bioimaging predictive markers -- Clinical translation -- Panel discussion -- Costs of clinical trials. Regulatory costs -- Patient accrual -- Global outsourcing -- Time is money -- Public-private collaborations -- Regulatory issues. Regulatory barriers to innovation -- Patient advocacy perspective -- Regulation of in vitro diagnostics -- Regulatory issues in improving cancer clinical trials -- Reports from the case study discussion groups. Adaptive trial design -- Phase 0 trials -- Imaging -- Use of proteomics/genomics to assign therapy in lung cancer -- Use of genetics/genomics to assign therapy Cancer Treatment United States Clinical trials |
| title | Improving the quality of cancer clinical trials workshop summary |
| title_auth | Improving the quality of cancer clinical trials workshop summary |
| title_exact_search | Improving the quality of cancer clinical trials workshop summary |
| title_full | Improving the quality of cancer clinical trials workshop summary National Cancer Policy Forum, Margie Patlack and Sharyl Nass, rapporteurs |
| title_fullStr | Improving the quality of cancer clinical trials workshop summary National Cancer Policy Forum, Margie Patlack and Sharyl Nass, rapporteurs |
| title_full_unstemmed | Improving the quality of cancer clinical trials workshop summary National Cancer Policy Forum, Margie Patlack and Sharyl Nass, rapporteurs |
| title_short | Improving the quality of cancer clinical trials |
| title_sort | improving the quality of cancer clinical trials workshop summary |
| title_sub | workshop summary |
| topic | Cancer Treatment United States Clinical trials |
| topic_facet | Cancer Treatment United States Clinical trials USA |
| work_keys_str_mv | AT patlakmargie improvingthequalityofcancerclinicaltrialsworkshopsummary AT nasssharylj improvingthequalityofcancerclinicaltrialsworkshopsummary AT nationalcancerpolicyforumus improvingthequalityofcancerclinicaltrialsworkshopsummary AT instituteofmedicineus improvingthequalityofcancerclinicaltrialsworkshopsummary |